Key result
Antidiabetic drug costs rise ~100% from 2018 to 2022, driven by non-insulin therapies.
Observational
Answers are grounded in this paper and cite their sources.
The economic burden of diabetes management in Romania is rapidly growing, driven largely by the increasing costs of non-insulin medications.
Diabetes mellitus is a major public health issue, with the number of cases continuously increasing. This results in significant direct and indirect costs, representing a massive economic burden on the healthcare system. In Romania, costs are covered through the National Diabetes Program, so analyzing the cost trends can help better allocate funds, potentially improving program efficiency in the long term. Using a retrospective descriptive study with data on medication and monitoring costs for diabetes patients in Constanța County from 2018-2022, provided by the National Health Insurance House, it was found that the total number of patients reimbursed for antidiabetic medications steadily increased, with costs in 2022 almost doubling compared to the start of the study period. Non-insulin medication generated the most significant costs, being 4-6 times higher than those for insulin. The results highlight the growing economic challenges associated with proper diabetes management, emphasizing the need for more efficient solutions to reduce costs.
No takes yet. Share an insight, caveat, or question.
Mihail et al. (2025) conducted an observational in Diabetes mellitus. Antidiabetic medications was evaluated on Medication and monitoring costs. Antidiabetic medication costs in Constanța County almost doubled from 2018 to 2022, with non-insulin medications generating 4-6 times higher costs than insulin.
Synapse has enriched 10 related papers. Consider them for comparative context: